卖掉临床CRO!药明康德提前引爆“雷点”

健识局
Oct 27, 2025

《生物安全法案》阴影刚消,药明就有了新的大动作。10月26日,药明康德做出了一个重大决定:出售全部中国临床服务研究业务,包括临床CRO和SMO业务。药明康德对外披露的消息是向高瓴投资私募股权基金公司,“打包出售”旗下临床试验服务的康德弘翼和药明津石的100%股权,价值28亿元。事实上,这两块资产分别是药明康德的临床CRO和SMO业务。康德弘翼资历“稍浅”,是药明康德与美国PRA Health ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10